Logo image of ADAG

ADAGENE INC-ADR (ADAG) Stock Fundamental Analysis

NASDAQ:ADAG - Nasdaq - US0053291078 - ADR - Currency: USD

2.03  -0.07 (-3.33%)

Fundamental Rating

2

Overall ADAG gets a fundamental rating of 2 out of 10. We evaluated ADAG against 572 industry peers in the Biotechnology industry. ADAG has a bad profitability rating. Also its financial health evaluation is rather negative. ADAG has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

ADAG had negative earnings in the past year.
In the past 5 years ADAG always reported negative net income.
In the past 5 years ADAG always reported negative operating cash flow.
ADAG Yearly Net Income VS EBIT VS OCF VS FCFADAG Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 -20M -40M -60M -80M

1.2 Ratios

With a decent Return On Assets value of -31.60%, ADAG is doing good in the industry, outperforming 65.10% of the companies in the same industry.
With a decent Return On Equity value of -56.28%, ADAG is doing good in the industry, outperforming 61.26% of the companies in the same industry.
Industry RankSector Rank
ROA -31.6%
ROE -56.28%
ROIC N/A
ROA(3y)-35.83%
ROA(5y)-34.76%
ROE(3y)-56.61%
ROE(5y)-50.5%
ROIC(3y)N/A
ROIC(5y)N/A
ADAG Yearly ROA, ROE, ROICADAG Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 -20 -40 -60 -80

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for ADAG so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ADAG Yearly Profit, Operating, Gross MarginsADAG Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 -2K -4K -6K

More info and screens

3

2. Health

2.1 Basic Checks

ADAG does not have a ROIC to compare to the WACC, probably because it is not profitable.
ADAG has more shares outstanding than it did 1 year ago.
ADAG has more shares outstanding than it did 5 years ago.
ADAG has a worse debt/assets ratio than last year.
ADAG Yearly Shares OutstandingADAG Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M
ADAG Yearly Total Debt VS Total AssetsADAG Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 50M 100M 150M

2.2 Solvency

Based on the Altman-Z score of -3.37, we must say that ADAG is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -3.37, ADAG is in line with its industry, outperforming 46.25% of the companies in the same industry.
A Debt/Equity ratio of 0.15 indicates that ADAG is not too dependend on debt financing.
The Debt to Equity ratio of ADAG (0.15) is worse than 67.89% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.15
Debt/FCF N/A
Altman-Z -3.37
ROIC/WACCN/A
WACC8.96%
ADAG Yearly LT Debt VS Equity VS FCFADAG Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 0 50M 100M 150M

2.3 Liquidity

ADAG has a Current Ratio of 2.50. This indicates that ADAG is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of ADAG (2.50) is worse than 70.33% of its industry peers.
A Quick Ratio of 2.50 indicates that ADAG has no problem at all paying its short term obligations.
ADAG has a Quick ratio of 2.50. This is in the lower half of the industry: ADAG underperforms 68.94% of its industry peers.
Industry RankSector Rank
Current Ratio 2.5
Quick Ratio 2.5
ADAG Yearly Current Assets VS Current LiabilitesADAG Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 50M 100M 150M

More info and screens

3

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 14.54% over the past year.
ADAG shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -96.40%.
The Revenue has been growing by 64.36% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)14.54%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-309.16%
Revenue 1Y (TTM)-96.4%
Revenue growth 3Y195.77%
Revenue growth 5Y64.36%
Sales Q2Q%-100%

3.2 Future

The Earnings Per Share is expected to grow by 10.30% on average over the next years. This is quite good.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y60.39%
EPS Next 2Y24.67%
EPS Next 3Y15.5%
EPS Next 5Y10.3%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ADAG Yearly Revenue VS EstimatesADAG Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 50M 100M 150M 200M
ADAG Yearly EPS VS EstimatesADAG Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 1 -1 -2

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

ADAG reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ADAG. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ADAG Price Earnings VS Forward Price EarningsADAG Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ADAG Per share dataADAG EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1

4.3 Compensation for Growth

A more expensive valuation may be justified as ADAG's earnings are expected to grow with 15.50% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y24.67%
EPS Next 3Y15.5%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ADAG!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ADAGENE INC-ADR

NASDAQ:ADAG (3/7/2025, 8:03:31 PM)

2.03

-0.07 (-3.33%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)N/A N/A
Earnings (Next)03-27 2025-03-27/amc
Inst Owners23.94%
Inst Owner Change29.28%
Ins Owners3.25%
Ins Owner ChangeN/A
Market Cap89.87M
Analysts77.78
Price Target10.31 (407.88%)
Short Float %0.14%
Short Ratio0.52
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)15.1%
PT rev (3m)11.8%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)5.05%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 110.16
P/FCF N/A
P/OCF N/A
P/B 1.59
P/tB 1.59
EV/EBITDA N/A
EPS(TTM)-0.72
EYN/A
EPS(NY)-0.75
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS0.02
BVpS1.28
TBVpS1.28
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -31.6%
ROE -56.28%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-35.83%
ROA(5y)-34.76%
ROE(3y)-56.61%
ROE(5y)-50.5%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-ScoreN/A
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity 0.15
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.5
Quick Ratio 2.5
Altman-Z -3.37
F-ScoreN/A
WACC8.96%
ROIC/WACCN/A
Cap/Depr(3y)96.93%
Cap/Depr(5y)83.68%
Cap/Sales(3y)10.85%
Cap/Sales(5y)39.62%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)14.54%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-309.16%
EPS Next Y60.39%
EPS Next 2Y24.67%
EPS Next 3Y15.5%
EPS Next 5Y10.3%
Revenue 1Y (TTM)-96.4%
Revenue growth 3Y195.77%
Revenue growth 5Y64.36%
Sales Q2Q%-100%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y9.54%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year51.42%
EBIT Next 3Y0.08%
EBIT Next 5YN/A
FCF growth 1Y42.11%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y41.46%
OCF growth 3YN/A
OCF growth 5YN/A